Skip to main content

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

Active, not recruiting · Phase 3 · NCT04622319

Conditions: HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer

At a glance

Research payments reported, 2025
$452,191
U.S. investigators named
24
Sites paid
33
Planned or actual enrollment
1,600

About the trial

Sponsor
Daiichi Sankyo (with AstraZeneca, NSABP Foundation Inc, GBG Forschungs GmbH, Spanish Breast Cancer Research Group)
Tested
DS-8201a (drug), T-DM1 (drug)
Dates
Started 2020-12-04; completion 2028-06-20
Results posted
Not yet

Patients with HER2-positive primary breast cancer (BC) who do not achieve complete response after appropriate neoadjuvant therapy are at higher risk of disease recurrence. More effective treatment options are needed for this patient population. This study will examine the efficacy and safety of trastuzumab deruxtecan (T-DXd) compared with trastuzumab emtansine (T-DM1) in high-risk patients with residual invasive breast cancer following neoadjuvant therapy.

From ClinicalTrials.gov, last updated 2026-05-15. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Daiichi Sankyo Inc. reported $452,191 in research payments for this study in 2025 (55 payments).

Products named: Enhertu

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.